Paradigm Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Paradigm Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-850	Closed	-$39.1K	–	635
2016 Q3	$39.1K	Hold	850	–	–	0.01%	564
2016 Q2	$42.7K	Hold	850	–	–	0.01%	594
2016 Q1	$45.5K	Hold	850	–	–	0.01%	605
2015 Q4	$55.8K	Buy	850 +50	+6%	+$3.09K	0.01%	642
2015 Q3	$45.2K	Hold	800	–	–	0.01%	660
2015 Q2	$47.3K	Buy	800 +100	+14%	+$6.17K	0.01%	656
2015 Q1	$43.6K	Sell	700 -200	-22%	-$11.6K	﹤0.01%	665
2014 Q4	$51.8K	Hold	900	–	–	0.01%	659
2014 Q3	$48.4K	Sell	900 -1,400	-61%	-$74.2K	0.01%	688
2014 Q2	$121K	Hold	2,300	–	–	0.02%	549
2014 Q1	$122K	Buy	2,300 +100	+5%	+$4.62K	0.02%	538
2013 Q4	$88.2K	Hold	2,200	–	–	0.01%	580
2013 Q3	$83.1K	Sell	2,200 -400	-15%	-$15.6K	0.01%	588
2013 Q2	$102K	Buy	+2,600	New	+$101K	0.02%	571

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Paradigm Asset Management's TEVA Position: Q4 2016 in Review

Paradigm Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 850 shares — an estimated $39.1K sold.

Paradigm Asset Management first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $122K in Q1 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Paradigm Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Paradigm Asset Management sold 850 Teva Pharmaceuticals shares in Q4 2016, an estimated $39.1K.
Paradigm Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Paradigm Asset Management's Teva Pharmaceuticals position peaked at $122K in Q1 2014.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Paradigm Asset Management's 13F filing for Q4 2016, filed 31 Jan 2017.